China's New Legal Power To Limit Or Block Mergers Could Signal Challenges Ahead For Global Pharmaceutical Alliances
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The Chinese Ministry of Commerce's wielding of a new Anti-Monopoly Law to block Coca-Cola's purchase of a local juice producer, and to impose severe restrictions on the combination of two other international businesses, could signal troubled times ahead for any global outfit operating in China that seeks to expand through a merger
You may also be interested in...
More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups
More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups
GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market